Skip to content

Elecsys free PSA 07027320190Recalls & reported problems

Roche Diagnostics GmbH · Class 3

All models of Elecsys free PSA (5)

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
2
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 04015630940011), received between Aug 17, 2018 and Jul 14, 2021 — classified as 2 malfunctions.

The most frequently reported specific device problem is “High Test Results” (2 reports).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Most reported problems

Device problems

  • High Test Results2
  • Insufficient Device Problem Information1

Patient problems

  • No Clinical Signs, Symptoms or Conditions1
  • No Consequences Or Impact To Patient1

Recent adverse event reports

The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.

  • MalfunctionJul 14, 2021High Test Results; Insufficient Device Problem Information; High Test Results; Insufficient Device Problem Information

    THE INITIAL REPORTER RECEIVED QUESTIONABLE ELECSYS FREE PSA IMMUNOASSAY AND ELECSYS TOTAL PSA IMMUNOASSAY RESULTS FOR ONE PATIENT TESTED ON A COBAS 8000 E 801 MODULE. PRIOR TO PATIENT TESTING, THE CUSTOMER CONFIRMED QC WAS ACCEPTABLE. THE PATIENT HAD A SAMPLE COLLECTED ON (B)(6) 2021 FOR FREE PSA AND TOTAL PSA TESTING. ON EACH DATE OF TESTING, THE INITIAL RESULTS WERE REPORTED OUTSIDE THE LABORATORY. THE CUSTOMER QUESTIONED THE REPORTED FREE PSA AND TOTAL PSA RESULTS. THE PATIENT'S SAMPLES WERE NOT REPEATED DUE TO THE SAMPLES BEING DISCARDED. ON (B)(6) 2021, THE PATIENT'S RESULTS WERE FREE PSA 4.240 NG/ML AND TOTAL PSA 1.34 NG/ML. ON (B)(6) 2021, THE PATIENT'S RESULTS WERE FREE PSA 4.810 NG/ML AND TOTAL PSA 1.630 NG/ML. THE CUSTOMER WAS UNSURE WHICH E 801 MODULE WAS USED FOR TESTING. THE E 801 MODULE SERIAL NUMBERS ARE (B)(4). THIS MEDWATCH IS FOR FREE PSA. REFER TO THE MEDWATCH WITH PATIENT IDENTIFIER (B)(6) FOR THE TOTAL PSA ASSAY.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 12167881 ↗
  • MalfunctionAug 17, 2018High Test Results; High Test Results

    THE CUSTOMER COMPLAINED OF QUESTIONABLE ELECSYS FREE PSA IMMUNOASSAY AND ELECSYS TOTAL PSA IMMUNOASSAY RESULTS FOR 1 PATIENT SAMPLE TESTED ON A COBAS 8000 E801 MODULE. THE CUSTOMER SUSPECTS THAT THERE IS AN INTERFERENCE PRESENT IN THE PATIENT SAMPLE. THIS MEDWATCH WILL COVER THE FREE PSA DATA. PLEASE REFER TO THE MEDWATCH WITH PATIENT IDENTIFIER (B)(6) FOR DATA ON THE TOTAL PSA. THE INITIAL FREE PSA RESULT WAS 3.87 NG/ML WITH REPEAT RESULTS OF 3.91 NG/ML AND 3.65 NG/ML. THE INITIAL TOTAL PSA RESULT WAS 3.00 NG/ML WITH REPEAT RESULTS OF 3.05 NG/ML AND 2.99 NG/ML. NO ERRONEOUS RESULTS WERE RELEASED OUTSIDE OF THE LABORATORY. THERE WAS NO ALLEGATION OF AN ADVERSE EVENT. THE COBAS E801 SERIAL NUMBER WAS (B)(4). THE INVESTIGATION IS CURRENTLY ONGOING.

    Patient problems: No Consequences Or Impact To Patient

    MAUDE report 7792760 ↗

Other Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions devices

All Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page